Results from the BETTER WISE trial: a pragmatic cluster two arm parallel randomized controlled trial for primary prevention and screening in primary care during the COVID-19 pandemic

Table 4 Demographic and clinical characteristics associated with differences in composite outcome score (N = 578)

	Δ Outcome (95% CI)	P value*
Intercept	0.27 (0.22, 0.33)	< 0.001
Randomization arm: control	reference	-
Intervention	0.03 (-0.01, 0.08)	0.163
Province: Alberta	reference	-
Newfoundland & Labrador	-0.22 (-0.28, -0.16)	< 0.001
Ontario	-0.20 (-0.26, -0.14)	< 0.001
Sex: Male	reference	-
Female	0.04 (0.01, 0.08)	0.018
Age: 40 – 44 years old	reference	-
45 – 49 years old	0.04 (-0.02, 0.09)	0.201
50 – 54 years old	0.07 (0.01, 0.12)	0.023
55 – 60 years old	0.05 (-0.01, 0.10)	0.116
> 60 years old	0.08 (0.02, 0.14)	0.013
Ethnic background: Caucasian	reference	-
Other ethnic background	-0.07 (-0.12, -0.02)	0.008
Education: ≥ 1-year post-secondary	reference	-
No post-secondary education	0.05 (0.01, 0.09)	0.027
GAD-2: Negative screen	reference	-
Positive screen	0.03 (-0.01, 0.08)	0.156

A fitted generalized estimating equation model with compound symmetric working correlation structure was used to estimate the parameters of the multivariate model. Data are expected difference in composite outcome relative to the reference condition for the variable. CI Confidence interval, GAD-2 Generalized Anxiety Disorder 2-item. The GAD-2 is a brief and easy to perform initial screening tool for generalized anxiety disorder. Scores range from 0 to 6. A score of 3 or more points is a positive screen for possible generalized anxiety disorder [30]
^*P values are based on two-sided Wald tests using robust covariance estimate

ISSN: 2731-4553